+34 620 10 75 37info@nanbiosis.com

Posts on Jan 1970

DR. CONXITA SOLANS received the “Pierre Fillet” Prize 2016 awarded by the Formulation Group of the French Chemical Society (SCF)

Conxita Solans, Scientific Director of the Unit 12 NANBIOSIS, received last July 4 in the opening ceremony of the congress Formula VIII, the award Pierre Fillet 2016, given by the Formulation Group of the French Chemical Society (SCF).

The prize was awarded to Dr Solans in recognition to her contributions on formulation of colloidal systems, namely on the design and characterization of Nanostructured Liquids such as nano-emulsions, microemulsions, micelles, etc, developed through Unit 12 of NANBIOSIS.

Pierre Fillet was a major force behind formulation in France particularly and across Europe, he was one of the instigators of the first Formula conference held in Nice in 1987. The prize is awarded to a well-recognized researcher whose work led to significant developments of any topic in formulation.


DR. CONXITA SOLANS received the “Pierre Fillet” Prize 2016 awarded by the Formulation Group of the French Chemical Society (SCF)
Read More

“MICELA PRIZE” by the Spanish Committee of Detergents, Surfactants and Related Products (CED) TO DR. CONXITA SOLANS

Dr. Conxita Solans, Scientific Director of the Unit 12 NANBIOSIS, has been awarded with the Micelle Prize, by the Spanish Committee of Detergents, Surfactants and Related Products (CED) The award was presented to Dr. Conxita Solans during the International Congress Formula VIII (Barcelona 4 to 7 July 2016),

The Formula Conferences cover all aspects in Formulation Sciences and Technologies and constitute a frame for knowledge transfer and dialogue between Academia and Industry. This annual event is organized jointly by various European Societies namely the French Chemical Society (SCF), the British Formulation Group of the Royal Society of Chemistry (FSTG/RSC), the German Society of Chemical Engineering and Biotechnology (DECHEMA, Germany), Scandinavia Chemical Societies (SP Chemistry) and the Spanish Group of Colloids and Interfaces of the Royal Societies of Chemistry and Physics (GECI/RSEQ-RSEF), as well as several companies (AKZO-NOBEL, BASF, BAYER and EVONIK, ensuring a truly and deep dialogue. The Formula VIII conference with the motto “Formulate your innovation. Innovate your formulation”  has highlighted that technical innovation and scientific discoveries in the chemistry field are the driving forces to offer breaking new products to the market.

The Comité Español de la Detergencia, Tensioactivos y Afines (CED) founded in 1957, is an independent entity constituted by National associations and enterprises related to the detergency, cosmetics, and detergent raw material industry. The Micelle Award is to recognize the participation and contributions to the conference organized annually by the CED for 46 consecutive years.

“MICELA PRIZE” by the Spanish Committee of Detergents, Surfactants and Related Products (CED) TO DR. CONXITA SOLANS.
Read More

Nanotechnology bio applications in the clinical diagnosis II: biosensor BiMW for the early diagnosis of bacterial infections in cirrhotic patients

The peritonitis bacterial spontaneous is an infection of the fluid ascetic that has high incidence in cirrhotic patients and is associated with a high mortality. In such situation, a diagnosis early is essential for the survival of the patient. However, the identification of the causative pathogen of infection is based currently on cultivation methods that are slow and laborious.

A research coordinated by the Group of Nanobiosensors and Bioanalytical applications of the CIBER-BBN, which coordinates Unit 4 of NANBIOSIS led by Laura Lechuga, has presented the development of a biosensor interferometric based in guides bimodal (BiMW), capable of identify and quantify E. coli in liquid ascetic reaching some limits of detection below them 100 cfu /mL in only 15 min of analysis. These results demonstrate the great capacity of the biosensor BiMW as a new tool in the field clinical for the analysis microbial due to its ease use and its good relationship of cost-effectiveness and speed in the microbiological analysis.

Article of Reference:  Label-free bimodal waveguide immunosensor for rapid diagnosis of bacterial infections in cirrhotic patients. Jesús Maldonado, Ana Belén González-Guerrero, Carlos Domínguez, Laura M.Lechuga. Biosensors and Bioelectronics.

Nanotechnology bio applications in the clinical diagnosis II biosensor BiMW for the early diagnosis of bacterial infections in cirrhotic patients
Read More

Nanotechnology bio applications in the clinical diagnosis: nanoplasmodic biosensor device for the early diagnosis of colorectal cancer

The group of Nano-biosensors and Bioanalytical applications of CIBER-BBN which coordinates Unit 4 of NANBIOSIS directed by Dr. Laura Lechuga, has led the final preparations of a technology with potential application in the early diagnosis of colorectal cancer, based in the detection of specific biomarkers in blood.
The nanoplasmonic biosensor based on LSPR (Localized Surface Plasmon Resonance) is generated on structured surfaces of nano discs of gold, that allow monitoring of biological interactions in real time and without the need of markers.
The nanoplasmonic biosensor allows analysis of human samples in a few minutes, without requiring reagents or additional instrumentation. The device is easy to use and its reduced dimensions offer an attractive opportunity for the development of point-of-care devices with potential to be used outside the laboratory.

Article of Reference:  Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer.Maria Soler, M. Carmen Estevez, Roi Villar-Vázquez, J. Ignacio Casal, Laura M. Lechuga. Analytica Chimica Acta. http://dx.doi.org/10.1016/j.aca.2016.04.059

Nanotechnology bio applications in the clinical diagnosis nanoplasmodic biosensor device for the early diagnosis of colorectal cancer
Read More

U26-S03. Metabolomic Studies (Remote) OUTSTANDING

Metabolomic Studies

Read More

U26-S02. NMR experiments in solid state (Remote) OUTSTANDING

NMR experiments in solid state

Read More

U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING

Acquisition of mono and bidimensional spectra

Read More

U24-S01 Evaluation of therapies for cardiovascular disease

Evaluation of therapies for cardiovascular disease

With cardiovascular disease consistently representing a major cause of death worldwide, a platform to perform experimental studies testing the efficacy of candidate therapies for CVD is necessary.
The methodology implemented in NANBIOSIS Unit 24 for this purpose has been tested and validated in several papers (Refs below). In brief, CVD is induced in a relevant large animal model (i.e. myocardial infarction and swine) using image guided surgical techniques (i.e. percutaneous balloon occlusion of a coronary artery for a pre-determined amount of time). Once the model is established, the therapy under study is applied and the experimental subjects followed up for a fixed length of time. Clinical grade imaging (i.e. Cardiac Magnetic Resonance including delayed enhancement) and laboratory techniques are used to follow up and document the evolution of the induced CVD. Generally, image acquisition is performed at baseline and serially during the predetermined duration of the study in order to study the effect of the therapy on measurable endpoints (i.e. left ventricular ejection fraction) to document improvement.

Customer benefits

The studies are tailored to the needs of each specific candidate intervention, can be implemented with different follow-up times and can be performed under regulatory requirements, since the performing institution is Certified for Good Laboratory Practices.
Thus the Service can be provided as proof-of-concept studies, full safety and efficacy or under GLPs to meet regulatory agencies’ guidelines and assure clinical translation, so that the customers can take their therapy to a clinical trial faster and more efficiently, thanks to the full range of capabilities offered in this service.

Target customer

The offered service can be of interest to scientists from academia willing to test a possible CVD therapy, including biologicals, small companies that have a candidate molecule which is promising enough to warrant large animal trials or big pharma willing to undergo GLP studies to commercialize their product.


  • Aimo A et al. Colchicine added to standard therapy further reduces fibrosis in pigs with myocardial infarction. J Cardiovasc Med (Hagerstown). 2023 Nov 1;24(11):840-846. doi: 10.2459/JCM.0000000000001554. Epub 2023 Sep 29. PMID: 37773884.
  • Österberg K et al. Personalized tissue-engineered veins – long term safety, functionality and cellular transcriptome analysis in large animals. Biomater Sci. 2023 May 30;11(11):3860-3877. doi: 10.1039/d2bm02011d. PMID: 37078624.
  • Pulido M et al. Transcriptome Profile Reveals Differences between Remote and Ischemic Myocardium after Acute Myocardial Infarction in a Swine Model. Biology (Basel). 2023 Feb 21;12(3):340. doi: 10.3390/biology12030340. PMID: 36979032; PMCID: PMC10045039.
  • Blanco-Blázquez V et al Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model. J Cardiovasc Dev Dis. 2023 Feb 17;10(2):86. doi: 10.3390/jcdd10020086. PMID: 36826582; PMCID: PMC9960949.
  • Arenal Á et al. Effects of Cardiac Stem Cell on Postinfarction Arrhythmogenic Substrate. Int J Mol Sci. 2022 Dec 19;23(24):16211. doi: 10.3390/ijms232416211. PMID: 36555857; PMCID: PMC9781106.
  • Báez-Díaz C et al. Intrapericardial Delivery of APA-Microcapsules as Promising Stem Cell Therapy Carriers in an Experimental Acute Myocardial Infarction Model. Pharmaceutics. 2021 Nov 1;13(11):1824. doi: 10.3390/pharmaceutics13111824. PMID: 34834235; PMCID: PMC8626005.
  • Crisóstomo V et al. The epicardial delivery of cardiosphere derived cells or their extracellular vesicles is safe but of limited value in experimental infarction. Sci Rep. 2021 Nov 12;11(1):22155. doi: 10.1038/s41598-021-01728-y. PMID: 34772964; PMCID: PMC8590017.
  • Prat-Vidal C et al. Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction. Cells. 2021 Sep 28;10(10):2571. doi: 10.3390/cells10102571. PMID: 34685551; PMCID: PMC8534140.
  • Ziani K et al. Characterization of encapsulated porcine cardiosphere-derived cells embedded in 3D alginate matrices. Int J Pharm. 2021 Apr 15;599:120454. doi: 10.1016/j.ijpharm.2021.120454. Epub 2021 Mar 5. PMID: 33676988.
  • Rossello X et al. CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions. Sci Rep. 2019 Dec 30;9(1):20290. doi: 10.1038/s41598-019-56613-6. PMID: 31889088; PMCID: PMC6937304.
  • Crisostomo V et al. Dose-dependent improvement of cardiac function in a swine model of acute myocardial infarction after intracoronary administration of allogeneic heart-derived cells. Stem Cell Res Ther. 2019 May 31;10(1):152. doi: 10.1186/s13287-019-1237-6. PMID: 31151405; PMCID: PMC6544975.
Read More

U20-S08. Immunotoxicity assays (On-site&Remote) OUTSTANDING

Immunotoxicity assays

Read More

U20-S07. In vivo PK/PD assays (Remote) OUTSTANDING

In vivo PK/PD assays

Read More